General Information of the Drug (ID: M6APDG03684)
Name
VER-54505
Synonyms
Cdk2 inhibitors, Vernalis; RBT-0049985
    Click to Show/Hide
Status
Investigative
TTD Drug ID
D0V1NK
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin-dependent kinase 2 (CDK2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for VER-54505. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of VER-54505 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for VER-54505. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VER-54505 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for VER-54505. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VER-54505 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
References
Ref 1 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973).
Ref 3 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.